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Abstract
To determine the potential of histamine H3 receptor (H3R) ligands as new
antiepileptic and procognitive drugs, aromatic ether derivatives (1-12) belonging to
the nonimidazole class of ligands, with high in-vitro binding affinity at human H3R,
were tested for their in-vivo anticonvulsive activity in maximal electroshock (MES)-,
pentylenetetrazole (PTZ)-, and strychnine (STR)-induced seizure models in male
adult rats having phenytoin (PHT) and valproic acid (VPA) as the reference
antiepileptic drugs, pitolisant (PIT) as the standard H3R antagonist/inverse agonist,
and donepezil (DOZ) as a reference procognitive drug. Among the H3R ligands (112) tested in the current project, H3R antagonist 4 showed significant and dosedependent reduction in the duration of tonic hind limb extension (THLE) subsequent
to acute systemic administration (5, 10, and 15 mg/kg, i.p.). Importantly, the
protective action observed for H3R antagonist 4 in MES-induced seizure was
comparable to that of the reference antiepileptic drug phenytoin (PHT), and was also
reversed when rats were pretreated with the CNS penetrant pyrilamine (PYR) (10
mg/kg, i.p.), or with the selective H3R agonist R-()-methylhistamine (RAMH) (10
mg/kg, i.p.). Furthermore, the procognitive studies indicate that acute pre-training
systemic administration of H3R antagonist 4 (2.5 mg/kg, i.p.) facilitated acquisition,
whereas pre-testing acute administration of 4 (5 and 10 mg/kg, i.p.) improved
retrieval. Interestingly, the procognitive effect of 4 on retrieval was completely
abrogated when rats were pretreated with the centrally-acting H2R antagonist
zolantidine (ZOL) but not the centrally acting H1R antagonist PYR, indicating that
histaminergic pathways through activation of H2Rs appear to be participating in
neuronal circuits involved in the retrieval processes. Taken together, our results show
that H3R antagonist 4 demonstrates anticonvulsant properties in the MES-induced
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seizure model and improves cognitive performance through actions on different
memory stages. Therefore, H3Rs may have implications for the treatment of
degenerative disorders associated with impaired memory function and may represent
a novel therapeutic pharmacological target to tackle cognitive problems associated
with the chronic use of antiepileptic drugs.

Keywords: Histamine H3 receptors, Antagonists, Anticonvulsant, Learning,
Memory, Passive avoidance test, R-()-methyl-histamine, Pyrilamine, Zolantidine
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)Title and Abstract (in Arabic

دراسة فعالية عدد من مثبطات مستقبالت الهستامين 3-المستخلقة حديثًا على نماذج
بحثية مختلفة للصرع وضعف الذاكرة في فصيلة معينة من القوارض
الملخص

انتشارا .يعتبر العالج
الصرع هو مرض مزمن ويعد من احد األمراض العصبية األكثر
ً
الدوائي أهم وسائل المعالجة لهذا المرض .لكن أدوية الصرع المتوفرة حاليًا فعالة لدى 07-07
ضا عن أن  % 07-07من الحاالت مازالت مستعصية باإلضافة لألعراض
 %من المرضى عو ً
الجانبية المصاحبة لهذه األدوية خاصة تلك التي تصيب الذاكرة .تم أجراء الكثير من الدراسات
مؤخرا حول صنف جديد من العالجات الدوائية يسمى مثبطات مستقبالت الهستامين(H3R 0-
ً
) antagonistsالستكشاف تأثيرها على كثير من األمراض العصبية والسلوكية(Pitolisant) .
يعتبر من أول مثبطات مستقبالت الهستامين 0-وصوال للدراسات السريرية ،وقد تخطى مراحل
متقدمة في كثير من هذه الدراسات بما فيها الصرع ،وضعف الذاكرة .لذلك قمنا في دراستنا هذه
باستخدام مركبات مختلفة ( )10-1ومشتقة من ) (Pitolisantولها نسبة ارتباط ثثبيطي عالية
بمستقبالت الهستامين 0-كما تشير الدراسات المخبرية .األهداف :هدف هذه الرسالة البحثية هو
دراسة فعالية هذه المركبات المستخلقة حديثًا على عدة نماذج بحثية ( (modelsللصرع وضعف
ضا عن ذلك ولغرض المقارنة،
الذاكرة على ذكور الجرذان البالغة من فصيلة ) .(Wistarعو ً
قمنا أيضا بفحص تأثير مركبات مستخدمة حاليا من قبل مرضى الصرع أو ضعف الذاكرة وهي
) )Valproic Acid) ،(Phenytoinو) .(Donepzilبداية قمنا بدراسة تأثير هذه المركبات،
باستخدام ثالث نماذج بحثية مختلفة ،على نوبات الصرع الناتج عن الصدمات الكهربائية
) )Maximal electric shockأو تلك الناتجة عن مواد كميائية وهي إما ( (Strychnineأو
( .(Pentylenetetrazolاعتمادًا على فعاليتها في تقليل أو منع هذه النوبات ،تم اختيار أفضل هذه
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المركبات لفحص تأثيرها على ضعف الذاكرة باستخدام ) .(Passive avoidance testالنتائج:
الحظنا اختالف تأثير هذه المركبات على نماذج الصرع البحثية المختلفة .لكن المركب  4تميز
بتأثيره القوي إحصائيًا على نوبات الصرع الناتجة عن الصدمات الكهربائية بحيث شابه تأثيره
تأثير ) (Phenytoinوللكن كان أشد فاعلية إحصائيًا مقارنة ب ) (Pitolisantعند الجرعة ( 17
ميليجرام /كيلوجرام) .هذا التأثير اعتمد على الهستامين كناقل عصبي حيث تم إبطال هذا
المفعول باستخدام كل من منشط مستقبالت الهستامين methylhistamine) (R-α- 0-ومثبط
مستقبالت الهستامين .(Pyrilamine) 1-اختلف تأثير هذا المركب على مراحل التعلم أو الذاكرة.
سنت إحصائيًا وبشكل كبير أحد مراحل الذاكرة المسماة
فالجرعة ( 0.2ميليجرام /كيلوجرام) ح ّ
باالكتساب ) .(acquisitionهذا التأثير لم يكن معتمدا على الهستامين كناقل عصبي حيث أن ً
كال
من مثبط مستقبالت الهستامين (Pyrilamine) 1 -ومثبط مستقبالت الهستامين(Zolantidine) 0-
فشل في إبطال مفعول هذه الجرعة من المركب  .4في المقابل ،كان لكل من الجرعتين ( 2و 17
ميليجرام /كيلوجرام) فاعلية كبيرة إحصائيًا في تقوية مرحلة أخرى من الذاكرة تسمى
باالسترجاع ) (Retrievalوتم إبطال مفعول الجرعة ( 17ميلجرام/كيلوجرام) بواسطة
سا على ذلك ،يمكن القول بأن تأثير هذه الجرعة اعتمد على الهستامين
) .(Zolantidineتأسي ً
كناقل عصبي تحديدًا من خالل تفاعل الهستامين مع مستقبالته العصبية .0-الخاتمة :في
المحصلة ،نتائجنا أظهرت أن المركب  4له خصائص مضادة لنوبات الصرع الناتجة عن
الصدمات العصبية هذا باإلضافة لقدرته على تحسين الذاكرة من خالل تأثيره على مراحل
مختلفة منها .لذلك فإن مثبطات مستقبالت الهستامين 0-قد تكون لها تطبيقات مستقبلية في عالج
مرض الصرع تحديدًا لتجنب أو معالجة مشاكل ضعف الذاكرة المصاحبة لكثير من أدوية
الصرع المستخدمة حاليا أو المصاحبة لمرض الصرع في حد ذاته.
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Chapter 1: Introduction

1.1 Histamine as a central neurotransmitter
Brain histamine (Figure 1) is a story that dates back to the early 20th century
when first-generation antihistamines were introduced at the time even before
histamine H1 or H2 receptors (H1-2Rs) were known. Sedation, a central side effect
associated with early antihistamines, raised speculation about a role for histamine in
the brain, particularly in regard to wakefulness. Kwiatkowski (1943) was the first to
isolate

histamine

from

brain

extract,

mainly

from

the

cortex.

Later,

electrophysiological studies in several brain regions and behavioural studies with
intracerebroventricular (i.c.v.) infusion of histamine demonstrated a potential new
neurotransmitter to be added to the existing neurotransmitter systems (Haas et al.,
2008). Furthermore, activity of neuronal histidine decarboxylase (HDC), histamine
synthesizing enzyme, which was known to exist in nerve endings, decreased in many
brain regions after lesions of the lateral hypothalamus (Garbarg et al., 1976,
Schwartz et al., 1976).

Figure 1: Chemical structure of histamine: 2-(1H-imidazol-4-yl) ethanamine

The breakthrough in the field of neuronal histamine was the production of
antibodies against HDC and histamine that were used to draw the first map of
neuronal histamine pathways utilizing histochemical methods (Watanabe et al., 1983,
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Panula et al., 1984). There are two storage compartments of brain histamine, one in
the synaptic vesicles of neuronal endplates and one in the mast cells (Verdiere et al.,
1975). Both compartments equally contribute to the levels of brain histamine since
W/WV knockout mice, in which mast cells are absent, lack around 50% of brain
histamine compared to their wild counterparts (Maeyama et al., 1983). W/WV
knockout studies and administration of 48/48 (Verdiere et al., 1975), a selective
histamine releaser from mast cell granules, can be used to differentiate between the
two histamine pools. Through their contact with the brain side of the blood brain
barrier, brain mast cells gate the interplay between the nervous, vascular and immune
systems. Their amounts decrease with age and vary between species, sex, and
pathological conditions (Silver and Curley, 2013).
1.2 Localization and projections of histaminergic neurons
Cell bodies of histamine neurons are confined in one area of the posterior
hypothalamus called tuberomammillary nucleus (TMN), i.e. between the
mammillary bodies and the optic chiasm of the tuber cinereum. Unlike other
aminergic neurons with separate nuclei, histaminergic cell bodies send projections to
different brain areas without a topographical pattern of their projections as confirmed
with retrograde tracers. One perikyra can send descending and ascending extensions
(Brown et al., 2001, Haas et al., 2008). Histamine neurons are heterogeneous
demonstrating distinct control mechanisms and innervating different brain regions
(Blandina et al., 2012). Histamine neurons are heterogeneous de Human brain
contains 64000 histamine neurons (Haas et al., 2008), 16 times higher than that in
rats, 4000 neurons (Ericson et al., 1987).

Histaminergic neurons send their

ascending and descending pathways to the cerebrum, brain stem and spinal cord,
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respectively (Figure 2). Through their extensions, histaminergic neurons rarely form
the classical synaptic contact with their targets. Instead, histamine is released from
varicosities, i.e. swellings along the axon, and spreads to the surrounding area like a
local hormone (Figure 3) affecting neuronal and non-neuronal components (Brown et
al., 2001, Haas et al., 2008).

Figure 2: Projections of TMN histamine neurons. Two ascending pathways: 1) ventral
part to the hypothalamus and septum, 2) dorsal part to the thalamus, hippocampus,
amygdala, and forebrain. One descending pathway to the brain stem, cerebellum and
spinal cord. Adopted from (Die Entwicklung von. (2010). Histamin-H3Rezeptorliganden als potenzielle Arzneistoffe und bildgebende pharmakologische
Werkzeuge (unpublished doctoral thesis). Institute for Pharmaceutical Chemistry,
Medcinal Chemistry Division, Goethe University, Frankurt/Main, Geramny).

Brain regions differ in amount of histaminergic fibers that they receive.
Ventrally, histaminergic neurons highly innervate the hypothalamus, diagonal band,
septum and olfactory tubercle. Amygdale, periventricular nuclei of the hypothalamus
and hippocampal subiculum, and the dentate gyrus receive the largest amount of
histaminergic fibers through the dorsal pathway. Other areas, like the cerebral cortex,
striatum, nucleus accumbens, tend to be moderately innervated. The Substantia nigra
and ventral tegmentum have more projections compared to the locus coeruleus and
raphe nuclei. Generally, the descending pathway incorporates the least fiber densities
(Brown et al., 2001).

4

1.3 Biosynthesis, release, and metabolism of central histamine
Histamine cannot pass through the blood brain barrier; thus it has to be
biosynthesized in situ. A dietary amino acid precursor of histamine is L-histidine can
pass through L-amino acid transporters (Figure 3) to the cerebrospinal fluid (CSF)
pool and the cytoplasm of neurons. Therefore, histamine biosynthesis depends on the
presence of this amino acid. Accordingly, L-histidine is converted to histamine
through oxidative removal of a carboxyl group by a specific enzyme, HDC, EC
4.1.1.22. At high concentration, histidine can be a substrate for nonspecific
decarboxylase (Prell et al., 1996). The nonspecific synthesis pathways can be
revealed with alpha-fluoromethyl histidine (α-FMH), an inhibitor of specific HDC.
Once synthesized, histamine is packed in vesicles in both soma and varicosities
through vesicular monoamine transporter-2 (VMAT-2). Upon depolarization of the
histamine neuron, calcium-dependent release of histamine occurs (Verdiere et al.,
1975). Histamine biosynthesis and release in the CNS is modulated by the histamine
H3 auto-receptors (H3Rs) through cAMP/PKA-dependent pathways (section 1.4.3)
(Bongers et al., 2007). Moreover, firing of central histaminergic neurons and release
of histamine is also controlled by inputs and receptors of other systems including
acetylcholine, norepinephrine, serotonin, and orexin among others (Brown et al.,
2001). Unlike other aminergic neurotransmitters, histamine has no known re-uptake
mechanism (Brown et al., 2001). However, the central action of histamine is
terminated via methylation by histamine N-methyltransferase (HNMT) in the
extracellular space to yield Ntele-methylhistamine which is then degraded by
monoamine oxidase B to t-methyl-imidazole acetic acid (Prell et al., 1996, Brown et
al., 2001, Haas et al., 2008).
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Figure 3: Neuronal histamine biosynthesis, release and metabolism in the CNS.
Adopted from (Haas et al., 2008).

1.4 Histamine receptors
The precise effects of histamine are exerted through stimulation of four
different G-protein coupled receptor (GPCR) subtypes, namely H1-H4R (Figure 4)
(Arrang et al., 1988; Arrang et al., 1987; Arrang et al., 1983, 1985a; Hill, 1990; Hill
et al., 1997; Lovenberg et al., 1999). All histamine receptors, to varying levels,
display constitutive activity (Bakker et al., 2000), i.e. have an active conformation
state that is independent of any ligand binding. Whereas H1-3Rs are highly
expressed in the brain. H4Rs have low expression, if any, in the CNS (see Schneider
and Seifert, 2015).
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Figure 4: Schematic illustration of main signaling pathways of human histamine
receptors hH1-4R. Modified after Strasser et al., 2015 (Sadek and Stark, 2015).

1.4.1 Histamine H1Rs in the Central Nervous System
H1R is coupled to the Gq/11 signaling pathway and has mainly excitatory
effects. However, inhibitory effects through calcium-induced activation of potassium
conductance are also possible. Furthermore, H1R is associated with formation of
arachidoinc acid (AA) and nitric oxide (NO) that can act as a retrograde messenger
controlling activity of pre-synaptic neurons however, the signaling pathway is yet to
be clarified (Brown et al., 2001, Haas et al., 2008).
H1Rs are primarily localized in brain regions involved in arousal and
cognition including the thalamus, cortex, cholinergic nuclei in the mesopontine
tegmentum and basal forebrain, aminergic nuclei in the locus corelus and raphe
nuclei, septal nuclei, hippocampus, and amygdale. Also, H1Rs exist in high density
in the nucleus accumbens, molecular layer of the cerebellum, nuclei of the cranial
nerves, area postrema, and nucleus tractus solitaries (Brown et al., 2001).
Interestingly, experimental studies with H1R KO mice have elucidated
abnormal circadian rhythm of locomotor activity (i.e. more active at light cycle),
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reduced exploratory activity in a novel environment, reduced anxiety and
aggressiveness, tapered pain sensitivity in different tests, selective changes in
different memory tests. The latter observations shed light on the importance of
histaminergic neurotransmission through central H1Rs. (Inoue et al., 1996, Yanai et
al., 1998, Mobarakeh et al., 2000, Dai et al., 2007b, Dere et al., 2008).
1.4.2 Histamine H2Rs in the central nervous system
The H2R is coupled to a Gs protein and is thus involved in the cAMP/PKA/
cAMP response element-binding protein (CREB) signaling pathway producing
excitatory effects like those observed in the CA1 region of the hippocampus,
pyramidal cells and thalamic neurons (Figure 4).
The H1- and H2Rs are colocalized in hippocampal pyramidal and granule
cells, and aminergic nuclei (locus coeruleus, raphe nuclei, substantia nigra, ventral
tegmental area). Further, H2Rs are present in high density in the basal ganglia and
amygdala. However, the receptor distribution is limited in the septal nuclei and the
hypothalamus where H1Rs predominate (Brown et al., 2001). Previous studies have
shown that H2R KO mice suffered test-specific cognitive dysfunction accompanied
by impaired hippocampal long-term potentiation (LTP) (Dai et al., 2007b).
1.4.3 Histamine H3Rs in the central nervous system
The H3R was discovered in 1983 in Paris using traditional pharmacology
(Schwartz, 2011). Its molecular sttructure was revealed almost a decade later in
efforts to identify an orphan GPCR that has widespread expression in the CNS
(Lovenberg et al., 1999). Employing genetic information from human H3R and RTPCR technology, many isoforms are obtained from alternative splicing of the human
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H3R gene as well as other species. These isoforms displayed heterogeneous
pharmacology, signal transduction, and distribution in the CNS (Drutel et al., 2001,
Hancock et al., 2003, Esbenshade et al., 2008), and will be further discussed below.
Human H3R (hH3R) protein sequence displays high homology to hH4R [38-58%]
(Liu et al., 2001, Morse et al., 2001, Zhu et al., 2001), however, very low homology
(21-22%) compared to hH1- and hH2Rs (Lovenberg et al., 1999).
As observed with other GPCRs in vitro, H3Rs display constitutive activity.
This activity was noted in vivo at normal physiological levels, unlike other GPCRs
(Morisset et al., 2000). GPCRs exist in equilibrium between their inactive and active
conformations. The quantity of the active conformations and how effectively they
couple to G-protein dictates the level of constitutive activity of the receptor. Inverse
agonists are agents that stabilize the inactive state and thus inhibit the constitutive
activity.
Although H3Rs do exist in the periphery (Ichinose et al., 1990, Taylor and
Kilpatrick, 1992, Imamura et al., 1995, Sugimoto et al., 2004, Hough and Rice,
2011), it has predominant, heterogeneous expression in the CNS (Lovenberg et al.,
1999). High densities of the H3Rs were found in the rostal part of the rat cerebral
cortex, hippocampus, amygdala, nucleus accumbens, striatum, olfactory tubercles,
cerebellum, substantia nigra, and brain stem. In addition, rat H3Rs were moderately
expressed in the hypothalamus and the cell bodies of histamine neurons (Panula et
al., 2015). In humans, H3Rs are found mainly in the basal ganglia, globus pallidus,
hippocampus and cortex (Martinez-Mir et al., 1990). This distribution is in concert
with their function in controlling the firing of histamine neurons and modulating the
synthesis and release of histamine as well as the release of other neurotransmitters
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including dopamine, serotonin, norepinephrine, acetylcholine, -aminobutiric acid
(GABA) and glutamate (Panula et al., 2015).
The H3R is a member of the GPCR family. Through the α-subunit of the Gi/o
protein (Gi/oα), H3Rs are negatively coupled to adenylate cyclase (Figure 4 and 5)
(Hancock et al., 2003, Bongers et al., 2007, Panula et al., 2015). In addition, H3Rs

Figure 5: Different possible signaling pathways of H3Rs. Adopted from (Bongers et al.,
2007).

were found to reduce intracellular calcium by Gi/oα-mediated suppression of N- and
P-type calcium channels in dissociated TMNs (Takeshita et al., 1998). There is a lack
of evidence supporting the coupling of H3R to inwardly rectifying potassium
channels as is the case for other autoreceptors. Therefore, the aforementioned Gi/oαmediated reduction in calcium influx seems to explain the observed histamineinduced inhibition of its own as well as other neurotransmitter release (Brown et al.,
2001, Hancock et al., 2003, Panula et al., 2015).
Also, reduced intracellular calcium was postulated to be the direct effector in H3R
agonist-induced reduction of norepinephrine release from noradrenergic nerve
terminals in the myocardium (Silver et al., 2002). The G-protein βγ-subunit of H3Rs,
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with possible complex interactions with other GPCRs, can activate other signaling
pathways including mitogen-activated protein kinase (MAPK), Akt/ glycogen
synthase kinase 3β (GSK3β) and phospholipase A2 (PLA2) (Figure 5) that are
involved in neuronal plasticity and brain disorders (Bongers et al., 2007, Panula et
al., 2015).
In contrast to H1- and H2R genes, H3R gene has many “species-distinct”
splice variants that result in the formation of a large number of isoforms (20 in
human) (Esbenshade et al., 2008). The isoforms include the supersized form [e.g.
hH3R (453) or rH3R (449)], the wild-type [445 amino acid] and the rest have shorter
protein sequences [e.g. hH3R (453), hH3R (220)] (Hancock et al., 2003). Eight of the
20 isoforms (in human) have been shown to be functional in heterogeneous
expression systems including [hH3R (445), (453), (415), (413), (409), (373), (365)
and (329)] (Esbenshade et al., 2008). Other H3R isoforms are either unstudied or
expected to be non-functional since they lack important domains essential for ligand
binding, carry a detrimental stop codon, or couldn’t assemble to a tertiary structure.
However, these functionally inert isoforms could have a physiological role by
altering the expression of other isoforms or changing the activity of other receptors
or proteins (Hancock et al., 2003, Bongers et al., 2007).
Different domains of H3R receptor (or any other GPCRs) have roles in
affinity to H3R ligands, efficacy in coupling to a variety of signal transduction
pathways or constitutive activity (Hancock et al., 2003, Arrang et al., 2007). Shorter
H3R isoforms, with deletion in various domains of the receptor, could have
dissimilar affinity or response to different H3R ligands. These dissimilarities are
augmented with differential distribution of these receptors in different brain regions
as indicated by real time- polymerase chain reaction (RT-PCR) studies (Bongers et
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al., 2007, Esbenshade et al., 2008). For example, compared to shorter isoforms, rat
H3R (rH3R) (445) appears to have more effective coupling to MAP kinase pathways,
which are important for synaptic plasticity. Interestingly, the same isoform has a
preferential localization in the hippocampus, a memory consolidation center (Drutel
et al., 2001). Thus, selective H3R (445) ligands would be more applicable in
cognitive disorders, like Alzheimer’s disease (AD).
Knockout studies have demonstrated Electroencephalography (EEG)confirmed enhanced vigilance and increased arousal during behavioral tests
including environmental change, locomotion and motivation tests (Gondard et al.,
2013), and general reduction of locomotor activity (Toyota et al., 2002) in H3R KO
mice. These H3R KO mice displayed sleep restriction (Gondard et al., 2013), and
loss of sensitivity to waking action of H3R antagonists and to memory impairing
effects of scopolamine (Toyota et al., 2002). Total absence of H3R was advantageous
in terms of cognition and reduced anxiety in response to avoidable stimuli (Rizk et
al., 2004).
1.4.4 Histamine H4Rs
Similar to H3Rs, these receptors are coupled to Gi/o protein yet, unlike H3Rs,
they are primarily expressed in the periphery (Zhu et al., 2001). Homology between
H3- and H4Rs, as mentioned above, results in pharmacological similarities between
the two receptors mainly with imidazole-containing compounds (Lim et al., 2005,
Haas et al., 2008). H4Rs are largely engaged in immunomodulation and their
expression predominates in cells and tissues of the immune system and by alteration
of their levels in response to inflammatory stimuli (Zampeli and Tiligada, 2009).
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1.5 Brain histamine in physiological and pathological conditions
In agreement with widespread projection of its neurons and several signaling
pathways coupled to its receptors, neuronal histamine is involved in multiple CNS
actions.

Brain

histamine

modulates

several

homeostatic

functions

like

thermoregulation, fluid balance, energy metabolism and stress. Histamine, also,
orchestrates biological rhythms, different behavioral states and higher brain activities
like cognition (Brown et al., 2001, Haas et al., 2008). In this section, some selected
histamine functions are described.
1.5.1 Epilepsy
Seizures are clinical manifestations of excessive excitation and abnormally
enhanced synchrony of neurons in a restricted region or in different parts of the
brain (Fisher et al., 2005). Epilepsy is a group of disorders characterized by a high
predisposition to recurrent seizures. The etiology of epilepsy can be due to genetic,
congenital, metabolic factors or secondary to stroke, trauma, tumors, drugs, alcohol
or medications. Mechanistically, these change intrinsic (e.g.; pumps, ion channels,
transporters) activity, alter synaptic transmission or cause “re-wiring” of neurons
resulting in reduced seizure threshold.
One of the main available strategies of pharmacotherapy for epilepsy is to
correct the imbalance between excitatory, glutamate, and inhibitory, GABA,
neurotransmission (Meldrum, 1995, Loscher, 2002, Stephen and Brodie, 2011). The
central histaminergic system in many studies has been shown to reduce or protect
from seizures. In preclinical studies, i.c.v. histamine prevented different types of
seizures (Table 1). Inhibition of N-methyltransferase, the histamine metabolizing
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enzyme in the CNS, by metoprine increased brain histamine content and reduced
seizure susceptibility (Tuomisto and Tacke, 1986, Onodera et al., 1992a, Kakinoki et
al., 1998, Yawata et al., 2004). Conversely, α-FMH, that diminishes histamine
synthesis, increased seizure activity (Zhang et al., 2003b). Similarly, HDC KO mice
were more prone to seizures (Hirai et al., 2004).
H1Rs seem to be the key mediators of histamine-induced elevation of seizure
threshold since centrally-acting H1R antagonists were shown to induce a
proconvulsant effect in several models (Yokoyama et al., 1996, Zhang et al., 2003b).
The proconvulsant action of H1R antagonists was prevented by histidine not
physostigmine indicating the involvement of histaminergic mechanisms (Kamei et
al., 2000).

H1R KO mice showed faster responses to amygdaloid and

pentelyenetetrazole (PTZ)-induced kindling (Chen et al., 2003, Hirai et al., 2004).
Clinically, children with febrile seizures had lower CSF histamine than those with
fever but no convulsions, suggesting an anti-seizure effect of histamine (Kiviranta et
al., 1995, Takano et al., 2010). Moreover, it has been found that H1R antagonists
increased the incidence of seizures in children (Miyata et al., 2011).
Table 1: Preclinical studies of H3R antagonists in different epilepsy models
Electrically-induced

Chemically-induced

Genetically-

seizures

seizures

encoded seizures

Histamine

↓ Amygdaloid-kindled

(i.c.v.)

in ratsb

Thioperamide

↓ Amygdaloid-kindled

↓ PTZ-induced in micea

↓ PTZ-induced in micec

and maximum electricshock in ratsd,e
Clobenopropit

↓Amygdaloid-kindled in

↓ PTZ-induced in ratsg

↓ EL micef
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Electrically-induced

Chemically-induced

Genetically-

seizures

seizures

encoded seizures

rats d,h
Pitolisant

↓ Maximum electric-

↓ KA-induced

↓spike-and-wave

shock in micei

hippocampal discharges

discharges (EEG) in

(EEG) in micei

the GAERS*i

↓KA-induced in micej

ABT-239

↓= Inhibit, reduce or delay seizures. PTZ= pentylenetetrazole, KA = Kianic Acid. *GAERS =
genetic absence epilepsy rats from Strasbourg. aYokoyama et al. (1994). bKamei (2001). cVohora
et al. (2000). dKakinoki et al. (1998). eHarada et al. (2004). fYawata et al. (2004). gZhang et al.
(2003a). hKamei and Okuma (2001). iKasteleijn-Nolst Trenite et al. (2013). jBhowmik et al.
(2014).

Furthermore, abnormal levels of H1Rs around the focus of epileptic injury in
complex partial seizures were observed in human positron emission tomography
(PET) studies (Tuomisto et al., 2001).
1.5.2 Arousal and sleep-wake cycle
Histaminergic neurons follow circadian rhythm in their firing and histamine
release. Their activity peaks at high vigilance state and diminishes during sleep
(Brown et al., 2001, Haas et al., 2008). TMN histaminergic neurons have a mutual
inhibitory interaction with the ventrolateral preoptic nuclei (VLPO), which is
involved in sleep regulation (Williams et al., 2014). The sedative effect of general
anesthetics is postulated to depend on GBAB-mediated inhibitory pathways from
VLPO to TMN neurons (Nelson et al., 2002, Moore et al., 2012). Histaminergic
neurons also receive

excitatory input (through orexin and glutamate as a co-

transmitter) from orexin neurons, which are involved in arousal (Schone et al., 2014).
Narcoleptic dogs with mutant orexin receptor-2 have lower histamine levels in their
thalami and cortices (Nishino et al., 2001). Furthermore, TMN neurons have

15

reciprocal interaction with other aminergic nuclei (involved in cortical activation).
Bilateral removal of the posterior hypothalamus leads to hypersomnia (Brown et al.,
2001). Interestingly, lower CSF histamine levels are observed in narcoleptic patients
(Nishino et al., 2009).
Pharmacologically, i.c.v. administration of histamine, H1R agonists, and oral
thioperamide (causes increase in histamine levels) promotes wakefulness or EEG
desynchronization. Their action is blocked by H1R antagonists. This suggests an
H1R dependence of this function supported by a lack of effect of selective H2R
antagonists in the sleep-wake cycle. Depletion of brain histamine by HDC inhibitor,
α-FMH, increased sleeping time (Brown et al., 2001, Haas et al., 2008). Similarly,
HDC KO displayed inability to stay awake in a new environment, a decreased EEG
activation during waking, and an increased paradoxical sleep (Parmentier et al.,
2002).
1.5.3 Cognition
Cognition is not just learning and memorizing. It, also, includes several
higher brain functions including attention, reasoning, problem solving and decision
making. The cognitive process is not controlled by certain parts of the brain but
rather it involves complex interactions between cortical and subcortical neuronal
pathways. Cognitive impairment may involve one or more aspects of cognition. For
instance, AD, a neurodegenerative disorder, is characterized by memory deficit while
attention is

impaired

in

attention-deficit

hyperactivity disorder

(ADHD).

Schizophrenia is associated with impairment of executive function, i.e. cognitive
inflexibility (Esbenshade et al., 2008).
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In order to evaluate cognitive processes, many tests have been developed to
analyze specific domains of cognition in animals as well as in clinical trials. In
memory tests, animals are trained or habituated to a certain environment or behavior
(utilizing fear or reward) during training sessions. Later during test sessions, animals
are reintroduced to the same environment and observed for signs of recall (test
session). For example, in contextual fear conditioning (CFC), animals receive a footshock in a novel environment during training sessions. During test sessions, animals
are returned to the same environment and a characteristic freezing behavior appears
as an indication of recall. Active (AVT) and passive (PAT) avoidance tests use footshock as an unpleasant consequence associated with a stimulus (light/sound) or an
intrinsic dark preference, respectively. PAT and ACT assess long-term memory.
Social recognition and object recognition tasks are short term memory tests that rely
on the animals ability to recall familiar olfactory cues (social interaction) or test
objects, respectively. In spatial memory tasks, animals are conditioned to link an
object, reward or punishment to a particular place (e.g., Barnes maze, water maze
and radial maze). Attentional set-shifting assays examine the animals ability to learn
and re-learn (cognitive flexibility). Attention is analyzed by 5-trial inhibitory
avoidance (5-trial IA) and 5-choice serial reaction time (5-CSRT) tests (Esbenshade
et al., 2008). Some behavioral tests in clinical trials share similarities to these animal
studies but take into account the complexity of the human brain. For pharmacological
testing, agents or lesions may be applied to induce deficiency in a region or a system
of the brain and to produce a memory deficit model. Scopolamine for example
induces memory impairment through an effect on cholinergic transmission (Flood
and Cherkin, 1986). Memory deficit can be introduced in animal strains through
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genetic manipulation as is the case for transgenic APPTg2576 mice, a model of AD
(McGowan et al., 2006).
Several preclinical studies indicate a role for histamine neurotransmission in
the cognitive process. In a previous study, inhibition of histamine synthesis in the
brain by α-FMH was found to reduce social recognition in rats (Prast et al., 1996). In
contrast, histamine (i.c.v.) facilitates memory in several tasks (Table 2). Moreover,
impairment of performance in several memory tests has been observed in mice
lacking H1- or H2Rs (Dai et al., 2007b, Dere et al., 2008). The selective H1R agonist
2-(3-(trifluoromethyl)-phenyl)histamine, through i.c.v. administration, enhanced
object recognition (Malmberg-Aiello et al., 2003). Clinically, the H1R antagonist
negatively influenced attention (Okamura et al., 2000). H1R binding was shown to
progressively decline in AD patients compared to their old, normal counterparts
(Higuchi et al., 2000). Similarly, postmortem AD brains had low histamine content
in the hypothalamus, hippocampus and temporal cortex (Mazurkiewicz-Kwilecki and
Nsonwah, 1989, Panula et al., 1998). H3R KO mice had enhanced place recognition
in the Barnes maze (Rizk et al., 2004). These mice were also resistant to
scopolamine-induced amnesia in PAT (Toyota et al., 2002). In parallel, the selective
H3R agonist RAMH increased forgetfulness in different memory models (Table 2).
Table 2: Preclinical behavioral characterization of H3R agonists and antagonists
Long-term
Working
Recognitio

Spatial

memory

Executive

Attention/

(fear

memory

impulsivity

memory
n memory

memory

memory)
Histamine
(i.c.v.)

↑ rats1,a

↑ rats2,b

↑ rats3,c

↑in rats1,d
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RAMH

↓ in rats1,e

Thioperamid

↑ rats1,4,a, f

↓ in rats1,e
↑ rats and
mice2,b, g

e
Ciproxifan

↑ rats1,2,l

↑ ratsh

↑ mice

↑ SHR

1,2,3,4,f, i, j

pupsk

↑in mice2,g

↑ SHR
pups and
rats1,m, n

Pitolisant

↑ mice1,2,o

GSK189254

↑rats1,q

↑ mice1,3,p
↑ in aged

↑ rats1,q

↑ rats1,q

rats1,q
SHR = spontaneously hypertensive rats (attention deficit). ↑= increase or improve, ↓= decrease
or worsen. 1Naïve animals, 2scopolamine-induced memory deficit, 3Dizocilpine-induced
memory deficit, 4PTZ-induced memory deficit. a(Prast et al., 1996). b(Chen and Kamei, 2000).
c
(Huang et al., 2003). d(de Almeida and Izquierdo, 1986). e(Blandina et al., 1996). f(Jia et al.,
2006). g(Komater et al., 2005). h=(Orsetti et al., 2002). i(Meguro et al., 1995). j(Charlier et al.,
2013). k(Komater et al., 2003). l(Pascoli et al., 2009). m(Fox et al., 2002). n(Day et al., 2007).
o
(Ligneau et al., 2007). p(Brabant et al., 2013). q(Medhurst et al., 2007).

1.5.4 Synaptic plasticity
In the process of memory formation, molecular and cellular changes occur to
enforce synapses that are essential for memory. These changes are called synaptic
plasticity and involve activation or inhibition of receptors, ion channels and proteins
with consequent alternation in the size and number of synapses (Middei et al., 2014).
Long-term potentiation (LTP) and long-term depression (LTD) are forms of synaptic
plasticity. The hippocampus is a brain structure that is highly involved in memory
consolidation and the most studied region in this regard.
Histamine was found to induce LTP in the CA1 region of the hippocampus in
vitro in the absence of any external tetanus stimulation that is usually employed in
such experiments (Selbach et al., 1997). On the other hand, impairment of
electrically-induced LTP was demonstrated in vitro in the CA1 region of H1 and H2
KO mice (Dai et al., 2007b). Such facilitation of synaptic activity could be attributed
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to: 1) activation of kinases like PKA (through H2R and potentiated by H1R) and
PKC (through H1R) and subsequent activation of other proteins, 2) mobilization of
intracellular Ca+2 stores by inositol triphosphate (IP3) (through H1R), 3) H1mediated removal of Mg+2 block from NMDA receptors and subsequent Ca+2 influx
and 4) H2R-mediated blockage of leak K+ conductance and increase of burst
discharges in CA3 with enhancement of its inputs to the CA1 (Brown et al., 2001,
Haas et al., 2008).
1.5.5 Locomotor activity and exploratory behavior
An important component of animal activity is locomotion, i.e. movement
from one place to another. It can be affected by many factors including external
stimuli (like introduction to a novel environment) or internal physiological
characteristics such as the circadian rhythm (Bevins and Besheer, 2001, Tosini,
2007). Impairment of locomotor activity is associated with several disorders
including Parkinson’s and Huntington’ diseases and hyperactivity syndrome. CNS
drugs can affect locomotion which can influence other behavioral parameters
including memory.
In several studies, histamine was found to enhance locomotion. Depletion of
brain histamine through pharmacological tools using α-FMH in ICR mice or by
genetic methods (HDC-KO) reduced novelty-induced or spontaneous locomotor
activity, respectively (Onodera et al., 1992b, Sakai et al., 1992, Kubota et al., 2002).
Sakai et al. (1992) demonstrated that higher brain histamine is associated with
increased locomotion. H1R KO mice showed impaired spontaneous activity (dark),
exploration, and rearing in a new environment (Inoue et al., 1996). Recently, it has
been shown that selective activation of histamine neurons increases locomotion (Yu
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et al., 2015). Moreover, previous results demonstrated that some H3R antagonists
increased the release of histamine and tendency to increased locomotion (Ghi et al.,
1998, Mohsen et al., 2014).
Contrary, depletion of histamine by α-FMH (in ICR mice but at higher dose:
100 mg/kg) was reported to increase locomotor activity and rearing (at night time)
which was accompanied by an 85% decrease in brain GABA (Sakai et al., 1995). In
addition, the imidazole-based H3R antagonist thioperamide was shown to decrease,
to various degrees, amphetamine/apomorphine/cocaine-induced hyperactivity, an
effect that was inhibited by the selective H3R agonist, namely (R)-α-methylhistamine
RAMH (Clapham and Kilpatrick, 1994). Indeed, the methamphetamine’s
hyperactivity effects were more pronounced in HDC-KO mice (Kubota et al., 2002).
Moreover, H1R antagonism increased locomotor activity with involvement of an
opioid-dependent mechanism (Leza et al., 1991). Histamine (i.c.v.) in rats had a
biphasic action: a transient augmentation then a reduction in locomotion (Haas et al.,
2008). Furthermore, H3R KO mice displayed reduced spontaneous locomotor
activity (Toyota et al., 2002).
1.6 Histamine H3R antagonists
1.6.1 Drug Development
Thioperamide (Figure 6) was the first potent H3R antagonist to be developed
as a research tool to explore the function of H3Rs. However, this agent was
associated with hepatotoxicity and the search began for more tolerable candidates
(Schwartz, 2011).
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Figure 6: Structural development of H3R antagonists by replacement of the
disadvantageous imidazole group.

Later, several compounds, like ciproxifan and clobenpropit, that share the
basic imidazole ring with thioperamide, were developed (McLeod et al., 2003). For
the latter imidazole-based antagonists, however, it has been shown that numerous
metabolic interactions may develop due to the ability of the imdazaole heterocycle to
potently inhibit CYP450 isoenzymes. Other class-related drawbacks of imidazolebased agents include relatively poor CNS penetration and incidence of off-target
activity at H4R or other receptors (Berlin et al., 2011, Panula et al., 2015). Therefore,
further chemical modulation, by replacing imidazole (Figure 6) with piperidine or
tertiary amine, resulted in the development of numerous non-imidazole H3R
antagonists which has attracted the main focus of the H3R antagonists design work in
recent years. Thus, the newer H3R antagonists, e.g. pitolisant, are seen as bioisosteric
alternatives to the imidazole-based group. Extensive structure-activity relationship
efforts in the field of drug design and development led to an understanding of the
general structural pattern (Figure 7) consisting of the most required pharmacophores
for a given compound to exert histamine H3R antagonistic affinity. The general
structural pattern (Figure 7) consists of a western basic moiety, that is connected via
an alkyl spacer to a hydrophilic (hetero-atom or -cycle) central core and an eastern
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part that is important for H3R antagonistic affinity and is only limited by the overall
molecular size.
1.6.2 H3 antagonists as candidates for the treatment of epilepsy and cognitive
disorders
Epilepsy is a serious neurological disorder that affects around 70 million
people worldwide from all age groups. The mortality rate is 3 times higher than the
normal population and the risk increases with uncontrolled cases. Pharmacological
intervention with antiepileptic drugs (AEDs) represents the chief strategy for the

Figure 7: General structural pattern of non-imidazole H3R
antagonists. Adopted from (Gemkow et al., 2009)

management of this ailment. Around 60-70 % of patients respond to treatment,
however, resistance to mono-therapy is not uncommon and drug combination is often
inevitable (Brigo et al., 2013). Available AEDs do not bear tolerable safety profiles
and, with poly-therapy, side effects are further augmented (Schmidt, 2002).
Cognitive impairment accompanies some types of epilepsy at onset and
worsens with chronic, poorly controlled seizures particularly in the developing brain
(Elger et al., 2004). Appropriate, early management of seizures removes the insult on
the brain cognitive function, though many AEDs themselves can negatively alter
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cognition (Hermann et al., 2010). Therefore, more effective, safer pharmacological
approaches that remove seizure risk and improve the quality of life are warranted.
Given their prominent expression and widespread distribution in the CNS, in
addition to their regulatory function on the release of histamine as well as other
neurotransmitters (refer to section 1.4.3), H3Rs are an attractive target for the
treatment of several CNS diseases including epilepsy and cognitive disorders. The
presence of different isoforms of the receptor with differential distribution in the
brain (refer to section 1.4.3) could permit the design of selective ligands with further
reduction of side effects.
1.6.2.1 H3R antagonists in epilepsy
As illustrated in Table 2, H3R antagonists attenuated or delayed convulsions
in several electrical, chemical or genetic models of epilepsy. This effect seems to
largely depend on H1R activation since it was reversed by CNS-penetrant H1R
antagonists (Kakinoki et al., 1998, Zhang et al., 2003a, Sadek et al., 2014). These
findings are supported by preclinical and clinical studies with H3R antagonists as
discussed in section 1.5.3. Furthermore, bicuculline, a GABAA receptor antagonist,
significantly diminished clobenpropit inhibition of amygdaloid kindling (Ishizawa et
al., 2000). Thus an association between H3R antagonist anticonvulsive action and
GABA transmission has been suggested. Accordingly, two scenarios are possible,
either 1) H3R antagonists inhibit autoreceptors and increase release of histamine that
in turn activates H1R and consequently excites GABAergic neurons and/or 2) H3R
antagonists

directly increase

heteroreceptors (Figure 8).

GABA

release

through

inhibition

of

H3R
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Figure 8: Schematic illustration of possible mechanisms by which H3R
antagonists affect seizures and cognition.

In addition, clobenpropit and iodophenpropit, H3R antagonists, exert
noncompetitive antagonism at the NR1/NR2B subunits of the NMDA receptors with
submicromolar potency (Hansen et al., 2010). NR2 (A, B, C or D) subunits, unlike
NR1, of NMDA receptors possess differential distribution and pharmacology (Vicini
et al., 1998). NR2A/B subunits are expressed abnormally in dysplastic neurons of
epileptic human cortex (Ying et al., 1999). Furthermore, selective NR1/NR2B
NMDA antagonists like ifenprodil, have anticonvulsant activity with no cognitive
side effects compared to non-selective NMDA antagonists (Chizh et al., 2001, Mares
and Mikulecka, 2009). Thus a synergistic action at H3R and NMDA receptors of
clobenopropit and iodophenpropit could explain their antiepileptic properties. Such
observations can be utilized to create more potent dual-target agents that can be used
for the management of epilepsy. Notably, H3R antagonists are progressing well in
clinical trials in the field of epilepsy. Recently, pitolisant showed promising
outcomes in proof-of-concept trials in a human photosensitivity model of epilepsy
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(Kasteleijn-Nolst Trenite et al., 2013). In this model, photosensitive, epileptic
patients are exposed to intermittent flashes of light at different frequencies before
and after test drug administration. These flashes at variable frequencies induce
subclinical epileptiform discharges on EEG (photo-paroxysmal responses) in
photosensitive patients. This model is an early “informative indicator” of AED’s
effectiveness and will help in dose selection for future phase 2/3 clinical trials (Yuen
and Sims, 2014).
Excessive excitation of neurons can lead to excitotoxicity and neuronal death.
Widespread neuronal necrosis can arise due to status epilepticus, prolonged or
rapidly recurrent seizures, even at its clinically-silent, non-convulsive stage
(Wasterlain et al., 1993). The neuronal damage that can occur during the status
epilepticus and thereafter can impair normal brain functions including cognitive
impairment, and potentiate further seizure activity, i.e. epileptogensis (Walker,
2007). Therefore, early intervention to prevent seizures is the first-line of protection
against seizure-associated neurotoxicity. Antiepileptic agents should also provide
neuroprotection and preserve normal brain activity (Walker, 2007). In previous
studies, the neuroprotective effects of H3R antagonists, e.g. thioperamide and ABT239, have been revealed in in vitro and in vivo kainic acid- or 3-nitropropionic acid
(3-NP)-induced neurotoxicity models (Kukko-Lukjanov et al., 2006, Bhowmik et al.,
2014). It has been observed that H3R up regulation and H1R down-regulation
coincided with excessive neuronal damage and behavioral effects as a consequence
of 3-NP-induced neurotoxicity in hamster and rat (Canonaco et al., 2005). Moreover,
the H3R antagonist clobenopropit prevented NMDA-induced neurotoxicity of
cultured cortical neurons by increasing GABA release mediated by cAMP/PKA (Dai
et al., 2007a). Furthermore, a previous study showed that the H3R antagonist ABT-
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239 protected against seizures and neuronal damage induced by kainic acid through
augmentation of PKA/CREB and Akt/GSK3βser9 signaling pathways that regulate
neuronal survival and inhibit excitotoxicity. Interestingly, these signaling pathways
are also involved in learning, memory and neuronal plasticity. In summary, H3R
antagonists have advantages over other available AEDs of possessing disease
modifying properties and may ameliorate cognitive decline that is associated with
epilepsy especially in the developing brain (Elger et al., 2004). Indeed, thioperamide
and JNJ-5207852 prevented different memory deficits induced by PTZ kindling in
weanling mice (Jia et al., 2006). Notably, H3R antagonists have cognitive enhancing
properties in other models as reviewed below.
1.6.2.2 H3R antagonists in cognition
Many H3R antagonists have been shown to facilitate learning and memory as
shown in Table 1. First possible etiology stems from their wake-promoting properties
in preclinical and clinical studies (Parmentier et al., 2007, Lin et al., 2011,
Dauvilliers et al., 2013). The arousal effect is combined with enhanced cortical fast
rhythms that are correlated with higher brain functions including alertness, attention
and cognition (Parmentier et al., 2007, Lin et al., 2011). Secondly, H3R antagonists
increase the synthesis and release of histamine and its associated memory
enhancement (Table 1). In addition, H3R antagonists can increase the release of
other neurotransmitters involved in cognition. Moreover, H3R antagonists increase
acetylcholine release in the prefrontal cortex, anterior cingulate cortex and
hippocampus (Mochizuki et al., 1994, Fox et al., 2005, Medhurst et al., 2007),
dopamine release in the prefrontal cortex and the anterior cingulated cortex (Fox et
al., 2005, Medhurst et al., 2007), and norephinephrine in the anterior cingulate cortex
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(Medhurst et al., 2007). The mechanism by which H3R antagonists influence other
neurotransmitter release is complex. It involves 1) excitation of the neurotransmitter
neuron through H1/H2, 2) excitation or inhibition of a “third-party” excitatory or
inhibitory neuron that in turn modulates neurotransmitter release and 3) direct
increase of the neurotransmitter release through inhibition of H3R heteroreceptors
(Figure 8 above).
Several H3R antagonists have entered phase 2 clinical trials to evaluate their
effectives against cognitive deficits associated with Schizophrenia, AD, and ADHD.
Two separate studies with the H3R antagonist GSK239512 have indicated its
beneficial effects in attention and memory in patients with mild-moderate AD
(Nathan et al., 2013, Grove et al., 2014). However, further larger scale testing is
required to clarify its effectiveness (Nathan et al., 2013). Interestingly, an essential
component or prerequisite of cognition is arousal and vigilance, both of which are
modulated by H3R neurotransmission. Wake-promoting effects have been
demonstrated with the H3R antagonists pitolisant (Inocente et al., 2012) and MK7288 (Sun et al., 2013). In addition, enhancement of cortical fast rhythms on EEG
has been observed with pitolisant (Kasteleijn-Nolst Trenite et al., 2013).
Supported by the evidence discussed above, the current study aimed to
investigate the activity of newly developed H3R antagonists (1-12) in several in vivo
epilepsy models, including MES-, PTZ- and strychnine (STR)-induced seizures. In
addition, selected H3R antagonist in terms of seizure control was nominated for
further cognitive in vivo tests in naïve animals utilizing PAT. The newly synthesized
H3R antagonists (1-12) belong to the non-imidazole class of compounds and possess
in vitro antagonistic binding properties in the nanomolar range at the human
histamine H3R.
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Chapter 2: Aims and Objectives

Previous studies have revealed the anticonvulsant and procognitive effects of
the imidazole-based H3R antagonists. Since the effects of non-imidzole based H3R
antagonists on memory and seizures in the same species are still unknown. Our main
aim was to investigate the effects of newly synthesized non-imidazole H3R
antagonists (1-12) of high in vitro antagonist affinities for hH3Rs, on their in vivo
anticonvulsant in MES-, (PTZ)-, and (STR)-induced seizures and procognirtive
effects in passive avoidance paradigm in male adult rats. The novel non-imidazole
H3R antagonists (1-12) were synthesized based on structure-activity relationship
studies of pitolisant and related derivatives and incorporated different alkyl spacers
(3, 5, or 6 methylene groups) and various aromatic substitutions (see Material &
Methods section).The detailed objectives of the experiments are as follows:
A. Investigate anticonvulsant effects of H3R antagonists 1-12 on MES-,
(PTZ)-, and (STR)-induced seizure models.
B. Dose-dependency of anticonvulsant effects provided by a selected H3R
antagonist in in terms of seizure control in MES, (PTZ), and/or (STR) seizure
models
C. Abrogation study of anticonvlusant effects provided by the selected H3R
antagonist in MES-, (PTZ)-, and/or (STR)-induced seizure models.
D. Memory-enhancing effects of a selected H3R antagonist offering the
greatest, histamine-dependent seizure control on acquisition, consolidation, and
retrieval stages in an inhibitory avoidance paradigm.
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E. Abrogation study of memory-enhancing effect provided by most effective
H3R antagonist on the level of acquisition, consolidation, and/or retrieval in an
inhibitory avoidance paradigm.
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Chapter 3: Materials and Methods

3.1 Animals
Male Wistar rats 180-200 g, bred at the Central Animal Facility of the UAE
University, were used. In the study, animals were maintained in an air-conditioned
room with controlled temperature (24±2 C) and humidity (55±15%) under a 12-h
light/dark cycle (lights on at 07:00 h). The animals were given free access to food
and water. Experiments were conducted between 9:00 and 15:00 h, and all
procedures were performed in accordance with the guidelines of the European
Communities Council Directive of 24 November 1986 (86/609/EEC) and were
approved by the Institutional Animal Ethics Committee of the College of Medicine
and Health Sciences, United Arab Emirates University (A9-14) for epilepsy and
(A30-13) for precognitive study.
3.2 Drugs
Phenytoin (PHT), valproic acid (VPA), R-(α)-methyl-histamine (RAMH), the
brain-accessible H1R antagonist pyrilamine (PYR) and H2R antagonist zolantidine
(ZOL), donepezil hydrochloride (DOZ), pentylenetetrazole (PTZ), and strychnine
(STR) were purchased from Sigma-Aldrich (St Louis, Missouri, USA). The test
compounds 1 and 2 were synthesized at the Institute of Pharmaceutical and
Medicinal Chemistry, Heinrich Heine University, Düsseldorf, Germany. The
standard H3R antagonist pitolisant (PIT) and the test compounds, namely the H3R
antagonists (3-12) were synthesized in the Department of Technology and
Biotechnology of Drugs, Kraków/Poland as described previously (Lazewska et al.,
2006) (Figure 9). The test compounds were dissolved in either 0.9% saline or

31

isotonic 10% DMSO and administered intraperitoneally (i.p.) at a volume of 1 ml/kg.
Doses of test compounds 1-12 as well as reference compounds were expressed in
terms of the free base.

Figure 9: Chemical structures of compounds used in this study. aCompounds were
purchased from Sigma-Aldrich (St Louis, Missouri, USA). bH3R antagonists were
synthesized in the Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine
University, Düsseldorf, Germany. cH3R antagonists were synthesized in the Department
of Technology and Biotechnology of Drugs, Kraków, Poland.

3.3 In vivo models of seizures
3.3.1 Maximal electric shock
MES is a model of generalized tonic-clonic seizures arising from the brain
stem on exposure to auricular stimulation. Through ear electrodes, an alternating
current with 50 Hz frequency and 120 mA intensity for 1-sec was applied to each rat.
Duration of tonic hind limb extension (THLE), tonic phase, was taken as a measure
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of seizures. Reduction in duration or complete absence of THLE was regarded or
defined as protection from seizures.
Animals were divided into different groups (a saline treated group and groups
receiving test compounds) each containing 7-8 rats. Saline, PHT 10 mg/kg (a
standard antiepileptic drug), PIT 10 mg/kg (a standard H3R antagonist), and test
compounds (1-12) each at dose of 10 mg/kg were injected i.p. 30 minutes before
shock application. H3R test compounds with significant protection against THLE
were then tested at other doses (5 and 15 mg/kg, i.p.) applying the same protocol to
explore dose dependency of the protective effect provided by the respective test
compound. In further experiments, rats were injected with the selected H3R
antagonist (test compound) offering the highest protection in combination with CNSpenetrant HR1 antagonist (PYR, 10 mg/kg, i.p.) to clarify the mechanism of seizure
protection.
3.3.2 Chemically induced seizures
PTZ, a GABAA antagonist, and STR, a glycine receptor antagonist, were the
two proconvulsant compounds used in the current study. Immediately after i.p.
administration of PTZ 60 mg/kg or STR 3.5 mg/kg (Loscher, 2011, Sowemimo et al.,
2011, Branco Cdos et al., 2013, Lopes et al., 2013), seizure activity was recorded for
30 minutes. Graded scores (0-5) were utilized to evaluate the resulting behavioral
phenomena (seizures) as the following: 0 = no seizures, 1 = eye or facial twitches, 2
= convulsive waves across the body, 3 = myo-clonic jerks or rearing, 4 = turn over
onto one side position, and 5 = turn over onto back position, generalized tonic-clonic
seizures, or die during the experiment period. Maximum seizure scores were
evaluated at 10-min intervals (10 min, 20 min and 30 min). Significant reduction of
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the maximum score at each time interval was regarded or defined as protection from
seizures at that interval.
Animals were divided into groups of 6-8 rats each according to the test
compounds. Saline, VPA 100 mg/Kg (in PTZ-induced seizure model), VPA 300
mg/kg (in STR-induced seizure model), PIT 10 mg/kg and test compounds (1-12)
each at 10 mg/kg were injected i.p. 30 min. before the administration of either PTZ
or STR. Test compounds that showed beneficial anti-seizure activity as defined
above were further tested at other doses ( 5 and 15 mg/kg, i.p.) against PTZ or STRinduced seizures to explore the dose dependency of their protective effect. In a
further experiment, the test compounds with the highest protection were co-injected
with PYR (10 mg/kg, i.p.) to clarify the mechanism of their anti-seizure effect in the
respective model (PTZ- or STR-induced seizure model).
3.4 Behavioral tests
3.4.1 Open Field Test
The open field test is a prerequisite for memory studies that require animal
movement and normal anxiety level. Any effect of compounds on the locomotor
activity or anxiety of animals could alter or confound their activity in the memory
test. Locomotor activity and anxiety levels were examined in an open field test
(OFT). A rectangular 112x56x56 cm3 (length/width/height) box that is open from
above provides the testing arena (Figure 10). The floor of the box was divided into
32 equal squares (14 cm in diameter). The 4 central squares were regarded as the
“center” of the field. At the beginning of the test, animals were transferred to the
arena only by their tails and placed in the center where they are allowed to move
freely for 3 minutes. During this time animal activity was recorded by a digital
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camera placed above the arena. Video recordings were utilized for assessment. When
a rat moved from one square to another with its four paws, one line crossing was
noted and a distance of 14 cm is recorded. The following parameters were manually
scored: the number of lines crossed and time spent in the center of the arena during a
3-minute test (Charlier et al., 2013). More time spent in the peripheral area was
usually taken as a measure of a higher level of anxiety and vice versa. After each
test, the arena was sprayed with 70% ethanol and wiped thoroughly to remove any

Figure 10: Open field arena utilized to explore locomotion and anxiety levels.
(A) Central area surrounded by a red square, when an animal stays in the center
it means low level of anxiety and vice versa. (B) No locomotion, animal is not
crossing any line or staying within a square. (C) Animal is about to cross a line,
i.e.14 cm distance is recorded.

residual odor. Animals were divided into groups of 7 rats each. 30 minutes prior to
the test, animals were injected i.p. with saline, PIT 10 mg/kg, DOZ 1 mg/kg or H3R
test compound 4 at various doses (2.5, 5 and 10 mg/kg, i.p.). Doses of H3R
antagonist 4 that didn’t significantly alter locomotor or anxiety levels were used for
subsequent memory tests.
3.4.2 Passive Avoidance Test (step-through)
The test was performed in a Passive Avoidance Apparatus (Step-through
Cage, 7550, Ugo Basile, Comerio, Italy). The apparatus consisted of two equal size

35

compartments (51 x 25 x 24 cm each) with grid floors which can be electrified
separately. The walls of the first compartment are painted white, and the second
compartment is dark with walls painted black. An automated guillotine door
separates the two compartments (Figure 11).

Figure 11: Passive avoidance test apparatus utilized in this study.

PAT is a long-term memory test. It consists of two types of session, namely a
training session and a test session separated usually by a 24 hour interval. This test
exploits the fact that rodents prefer a dark environment. Each rat was introduced to
the white compartment for 30 seconds to explore then the door separating the dark
chamber was automatically opened. Within a minute or less, rats should move to the
dark or otherwise would be excluded from the study. When animals reached the dark
compartment with all four paws, the door was closed within 3 seconds and an
inescapable foot shock (intensity = 0.5 mA, duration= 3 seconds) was administered.
This concluded the training session and 70 % ethanol was used to clean the
compartments to remove olfactory cues after each experiment. In the same manner
and 24 hr later the animals were again placed in the white compartment and 300
seconds as a cut-off time was provided while the door was open. Once the rats
moved to the dark compartment, the test was ended without any foot shock to be
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delivered. The latency to move to the dark compartment (step-through latency) was
utilized to evaluate the memory of the animals. Higher latency indicated better recall.
To investigate the effect of test compound 4 on several components of
memory formation, H3R antagonist 4 was injected in separate groups of animals at
different time points (Figure 12). Drugs were given 30 minutes before the training
session (time point 1), directly after the training (time point 2) or 30 minutes before
the test session (time point 3). These three separate experiments were employed to
explore their activity in memory acquisition, consolidation or retrieval, respectively.

Figure 12: Schematic description of passive avoidance test protocol and time
points of injections to test effect of a compound in several aspects of memory:
acquisition, consolidation and retrieval.

To reduce the number of animals and even out experience of injection among all
animals, all the groups received saline injection at all three time points, except when

37

the compound was given, (Figure 12) and one control group (only saline treated at all
time points) was used for comparison.
Any memory-improving effect of the selected H3R antagonist 4 was then
further investigated by abrogation studies that included co-administration of the most
effective dose of H3R antagonist 4

and zolantidine (ZOL, 10 mg/kg, i.p.) or

pyrilamine (PYR, 10 mg/kg, i.p.). Doses of ZOL and PYR were selected according
to previous studies (Orsetti et al., 2001, Sadek et al., 2013, Sadek et al., 2014).
3.5 Statistical analysis

For statistical comparisons, the software package SPSS 20.0 (IBM Middle
East, Dubai, UAE) was used. All data were expressed as the means ± SEM. All the
results were analyzed using one-way ANOVA analysis of variance (ANOVA) with
Treatment (vehicle or test compound) and Dose (test compound) as the betweensubjects factor. In case of a significant effect, post hoc comparisons were performed
with Bonferroni's test. The criterion for statistical significance was set at a P value of
less than 0.05.
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Chapter 4: Results

4.1 Effect of H3R antagonists 1-12 on MES-induced seizures
Figure 13 shows the protective effects of acute systemic administration of test
compounds 1-12 on MES-induced seizures in rats. One-way analysis of variance
showed that treatment with PHT, PIT, and H3R ligands 1-12 (10 mg/kg, i.p.) exerted
a significant protective effect against MES-induced convulsions [F(14,90) = 34.422;
P<0.05]. Among the compounds tested 4, 8, 10, 11, and 12 provided the best
protection against MES-induced convulsion in rats pretreated with 10 mg/kg, i.p.
when compared with the saline-treated group [F(1,12) = 235.86, 16.52, 53.04, 25.99,

Figure 13: Protective effect of an intraperitoneal injection of H3R antagonists 1-12 on
maximal electroshock-induced seizure. The figure shows the protective effects of
phenytoin (PHT, 10 mg/kg, i.p.), pitolisant (PIT, 10 mg/kg, i.p.), and H3R antagonists
1–12 (10 mg/kg, i.p.) on the duration of tonic hind limb extension (THLE) induced in
the maximal electroshock (MES) model in rats. Data are expressed as mean ± SEM
(n=7). *P<0.05 vs. the saline-treated group. **P<0.001 vs. saline-treated, group.
#
P<0.001 vs. PIT (10 mg)-treated group.
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77.37, and 11.66, respectively, P< 0.05]. When compared with the group pretreated
with PIT (10 mg/kg, i.p.), only H3R antagonist 4 showed significantly higher
protective effect on MES-induced seizures [F(1,12) = 41.65, P<0.05]. Also, the
protective effect observed for H3R antagonist 4 (10 mg/kg, i.p.) was comparable to
those observed with PHT-treated group [F(1,12) = 1.66, p=0.22, NS].
4.2 H3R antagonist 4 dose-dependently reduced MES-induced seizures
Figure 14 shows the protective and dose-dependent effects of acute
administration of H3R antagonist 4 (5, 10 or 15 mg/kg, i.p.) on MES-induced
seizures in rats. One-way analysis of variance showed that pretreatment with PHT
(10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), and 4 (5, 10, and 15 m/kg, i.p.) exerted
significant protective effects against MES-induced convulsions [F(5,36) = 83.05; P <
0.05]. Moreover, significant increases in protective effects were observed after
pretreatment with 10 and 15 mg/kg of 4 when compared with 5 mg/kg of the same
compound [F(1,12) = 74.59 and F(1,12) = 92.86; P < 0.05], respectively.
Also, the protection observed for H3R antagonist 4 (5, 10 and 15 m/kg, i.p.)
was significant when compared with the saline-treated group [F(1,12) = 31.35, F(1,12) =
235.87, and F(1,12) = 257.19, respectively, P < 0.05]. The results, also, show that H3R
antagonist 4 exhibited the highest protection against MES-induced convulsion in rats
pretreated with 10 and 15 mg/kg, i.p. and were similar to the protective effects
observed for the standard AED PHT (10 mg/kg, i.p.) [F(1,12) = 1.66, and F(1,12) = 1.96,
respectively, all P < 0.05].
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Figure 14: Dose-dependent protective effects of H3R antagonist 4 against maximal
electroshock (MES)-induced seizures. The figure shows the protective effects of
phenytoin (PHT, 10 mg/kg, i.p.), pitolisant (PIT, 10 mg/kg, i.p.), and H3R antagonist 4
(5, 10, 15 mg/kg, i.p.) on the duration of tonic hind limb extension (THLE) induced in
MES model in rats. Data are expressed as mean ± SEM (n=7). *P < 0.001 vs. the salinetreated group. #P < 0.001 vs. 5 mg H3R antagonist 4. &P < 0.001vs. PIT-treated group.

4.3 H3R antagonist 4-induced shortening of THLE duration was abrogated by
PYR and RAMH in MES-induced seizures
Figure 15 shows reversal of the protective effects of H3R antagonist 4 by
pretreatment with 10 mg/kg of the CNS penetrant histamine H1R antagonist
pyrilamine (PYR) 30 min, and with 10 mg/kg of RAMH 15 min before MES
challenge with [F(1,12) = 12.38, for the comparison between 4 + PYR and 4 alone],
and [F(1,12) = 66.67, for the comparison between 4 + RAMH and 4 alone].
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Figure 15: Effect of PYR and RAMH pretreatment on the protection by H3R
antagonist 4 on maximal electroshock (MES)-induced convulsions in rats. Saline,
H3R antagonist 4 (10 mg/kg), H3R antagonist 4 (10 mg/kg) + PYR (10 mg/kg),
saline + PYR (10 mg/kg), H3R antagonist 4 (10 mg/kg) + RAMH (10 mg/kg, and
saline + RAMH (10 mg/kg) were injected 30 min before electroshock. Effects shown
are expressed as the duration of tonic hind limb extension (THLE) induced in the
MES model in rats. Data are expressed as mean ± SEM (n= 7). *P < 0.001vs. the
saline-treated group.

4.4 Effect of H3R antagonists 1-12 on PTZ-induced seizures
Figure 16 shows the effects of H3R ligands 1-12 (10 mg/kg, i.p.) and the
standard H3R antagonist PIT in comparison to the protective effects of the reference
antiepileptic drug VPA in PTZ-induced seizures in rats. In PTZ-induce seizure, H3R
ligands 5, 6, and 12 provided significant protective effects relative to the salinetreated group after 10, 20, and 30 min of observation [P < 0.05]. Among the most
effective compounds, only H3R ligand 6 provided full protection when compared
with saline-treated group after 10, 20, and 30 with [F(1,12) = 101.4; P < 0.05], [F(1,12)
= 44.74; P < 0.05], and [F(1,12) = 16.8; P < 0.05], respectively. However, H3R ligand
4 (10 mg/kg, i.p.) did not provide significant protective effect relative to the salinetreated after 10, 20, and 30 min [F(1,12) = 0.10, 3.68, and 0.021, respectively, all NS].
Similarly, PIT failed to provide protection in the PTZ-induced seizure model after
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10, 20, and 30 min [F(1,12) = 0.03, 0.01, and 0.50, respectively, all NS]. However,
VPA (VPA 100 mg/kg) provided significant protection when compared with salinetreated group after 10, 20, and 30 min with [F(1,12) = 101.4; P < 0.005], [F(1,12) =
44.74; P < 0.05], and [F(1,12) = 16.8; P < 0.05], respectively.

Figure 16: Protective effect of pretreatment with H3R antagonists 1-12 on
pentylenetetrazole (PTZ)-induced seizures in rats. Valproic acid (VPA, 100 mg/kg, i.p.)
as a reference AED in PTZ-induced seizure (Serdiuk and Gmiro, 2014), 10 mg of
pitolisant (PIT), and 10 mg of the respective H3R antagonist were injected i.p. 30 min
before PTZ (60 mg/kg, i.p.) treatments. Effects shown are expressed as score of seizures
after 10 min, 20 min and 30 min of PTZ injection. Data are expressed as the mean ±
SEM (n=7). *P<0.05 vs. the saline-treated group.&Full protection for VPA (100 mg/kg,
i.p.), H3R antagonists 5 (after 30 min), 6 (after 10, 20, and 30 min), and 12 (after 30
min).

4.5 Dose-dependent effects of H3R antagonist 6 on PTZ-induced seizures
Figure 17 shows the protective and dose-dependent effects of acute
administration of H3R ligand 6 (5, 10 or 15 mg/kg, i.p.) on PTZ-induced seizures in
rats. One-way analysis of variance showed that pretreatment with reference
antiepileptic drug VPA and H3R ligand 6 (5, 10, and 15 m/kg, i.p.) exerted a
significant protective effect against PTZ-induced convulsions with [F(3,24) = 53.55; P
< 0.05], [F(3,24) = 24.13; P < 0.05], and [F(3,24) = 10.50; P < 0.05] for 10, 20, and 30
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min observation, respectively. The results showed that significant and full protective
effect was provided at 10, 20, and 30 min after pretreatment with 10 and 15 mg/kg of
H3R antagonist 6. Comparable full protection was observed with 5 mg/kg of H3R
antagonist 6 only at 30 min [F(1,12) = 14.00; P < 0.05 for 30 min] , yet significant
protective effect of lesser magnitude was recorded at 10 and 20 min [P < 0.05 for 10
and 20 min].

Figure 17: Dose-dependent protective effects of H3R antagonist 6 against
pentelenetetrazole (PTZ)-induced seizures. The figure shows the protective effects
of Valproic acid (VPA, 100 mg/kg, i.p.) as a reference AED and H3R antagonist 6
(5, 10, 15 mg/kg, i.p.) on the score of PTZ-induced seizure model in rats. Effects
shown are expressed as score of seizures after 10 min, 20 min and 30 min of PTZ
injection. Data are expressed as mean ± SEM (n=7). *P < 0.001 vs. the saline-treated
group. &Full protection.

4.6 H3R antagonist 6-provided protection was partially abrogated by PYR in
PTZ-induced seizures
Figure 18 shows the protective effect of H3R ligand 6 when co-administered
with 10 mg/kg of the CNS penetrant histamine H1R antagonist pyrilamine (PYR) 30
min before PTZ challenge [F(1,12) = 37.75 (P < 0.05) and 6.50 (P < 0.05) for the

44

comparison between H3R ligand 6 + PYR and H3R ligand 6 alone for 10 min and 20
min of observation, respectively; all P < 0.05]. However, and only after 30 min
of observation , the protective effect of H3R ligand 6 was reversed by pretreatment
with pyrilamine (PYR) [F(1,12) = 0.08; P=0.78 for the comparison between H3R
ligand 6 + PYR and H3R ligand 6 alone for 30 min of observation].

Figure 18: Effect of PYR pretreatment on the protection by H3R antagonist 6 against
pentelenetetrazole (PTZ)-induced seizures in rats. Saline, H3R antagonist 6 alone,
H3R antagonist 6 (10 mg/kg) + PYR (10 mg/kg) or saline + PYR (10 mg/kg) were
administered 30 min before PTZ injection. Effects shown are expressed as score of
seizures after 10 min, 20 min and 30 min of PTZ injection. Data are expressed as
mean ± SEM (n=7). *P < 0.05 for seizure scores vs. the saline-treated group. &Full
protection.

4.7 Effect of H3R antagonists 1-12 on STR-induced seizures
Figure 19 shows the effects of H3R ligands 1-12 (10 mg/kg, i.p.) and the
standard H3R antagonist PIT in comparison to the protective effects of reference
antiepileptic drug VPA in STR-induced seizures in rats. In STR-induced seizure,
H3R ligands 8 and 11 provided significant protective effects relative to the saline-
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treated group after 10, 20, and 30 min of observation [P < 0.05]. The results showed
that H3R ligand 8 provided significant protection when compared with saline-treated
group after 10, 20, and 30 with [F(1,12) = 24.08; P < 0.05], [F(1,12) = 40.33; P < 0.05],
and [F(1,12) = 20.74; P < 0.05], respectively.
Also, H3R antagonist 11 (10 mg/kg, i.p.) provided significant protective
effect relative to the saline-treated after 10, 20, and 30 min of observation [F(1,12) =
12.10; P < 0.05, F(1,12) = 5.113; P < 0.05, F(1,12) = 19.09; P < 0.05, respectively.
Moreover, the standard H3R ligand PIT (10 mg/kg, i.p.) failed to provide protection
in STR-induced seizure model after 10, 20, and 30 min [F(1,12) = 0, 3.32, and 3.50; all
NS], respectively. However, VPA (VPA 300 mg/kg, i.p.) provided significant
protection when compared with saline-treated group after 10, 20, and 30 with [F(1,12)
= 41.82; P < 0.05], [F(1,12) = 144.15; P < 0.05], and [F(1,12) = 81.82; P < 0.05],
respectively.

Figure 19: Protective effect of pretreatment with H3R antagonists 1-12 on strychinine
(STR)-induced seizures in rats. Valproic acid (VPA, 300 mg/kg, i.p.) as a reference AED
in STR-induced seizure (Serdiuk et al., 2014), 10 mg of pitolisant (PIT), and 10 mg of
the respective H3R antagonist 1-12 were injected i.p. 30 min before STR (3.5 mg/kg,
i.p.) treatments. Effects shown are expressed as score of seizures after 10 min, 20 min
and 30 min of STR injection. Data are expressed as the mean ± SEM (n=7). *P<0.05 vs.
the saline treated group. &Full protection.
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4.8 Effects of H3R antagonist 4 on acquisition
Figure 20 shows no significant effects of H3R antagonist 4 (5 and 10 mg/kg,
i.p.), PIT (10 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on memory acquisition in the one
trial inhibitory avoidance task [F(5,40) = 1.75; P=0.14]. However, only rats pretreated

Figure 20: Effect of pre-training administration of H3R antagonist 4 on acquisition in
an inhibitory avoidance conditioned response in adult male rats. Gray columns
represent the mean step-through latencies measured during the retention test (test
latencies) and black columns the mean step-through latencies measured during the
training trial before the delivery of the foot-shock (pre-shock latencies). Rats were
injected with H3R antagonist 4 (2.5, 5 or 10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), or
donepezil (DOZ, 1 mg/kg, i.p.) 30 min before the training session. Memory retention
was measured 24 h after training. *P < 0.005 for mean step-through latencies vs. the
value of the saline group. Data are expressed as mean ± SEM (n=7).

in the pre-training session with H3R antagonist 4 (2.5 mg/kg, i.p.) showed a
significant effect on step-through latencies when compared with the saline-treated
with [F(1,12) = 12.09; P < 0.05]. Surprisingly, higher doses of H3R ligand 4 (5 and 10
mg/kg, i.p.), PIT (10 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) failed to improve
performance of rats treated in the pretraining session with [F(1,13) = 4.26, F(1,13) =
0.04, F(1,12) = 3.46, and F(1,14) = 3.87; all NS], respectively.
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4.9 Effect of PYR and ZOL on the H3R antagonist 4-provided memory
improvement of acquisition in an inhibitory avoidance conditioned response
Figure 21 shows the results of the experiment testing whether the H3R
antagonist 4 (2.5 mg/kg)-induced improvement of acquisition was mediated through
histaminergic neurotransmission. For this purpose, a group of rats (n=7 for each

Figure 21: Effect of PYR and ZOL on acquisition improvement of H3R antagonist 4
in an inhibitory avoidance conditioned response in rats. Gray columns represent the
mean STLs measured during the retention test (test latencies) and black columns the
mean STLs measured during the training trial before the delivery of the foot-shock
(pre-shock latencies). Rats were injected with Saline + 4 (2.5 mg/kg), 4 (2.5 mg/kg)
+ PYR (10 mg/kg), 4 (2.5 mg/kg) + ZOL (10 mg/kg), Saline + PYR (10 mg/kg), or
Saline + ZOL (10 mg/kg) 30 min before the test session. *P < 0.05 for mean STLs vs.
the value of the (Saline)-treated group. Data are expressed as mean ± SEM (n=7).

group) was injected with Saline + 4 (2.5 mg/kg), Saline + 4 (2.5 mg/kg) + PYR (10
mg/kg), or 4 (2.5 mg/kg) + ZOL (10 mg/kg) 30 min before the test session. As
depicted in Figure 21, one-way ANOVA repeated measure with Treatment as the
between-subject factor indicated a significant effect of this factor on latency time
[F(5,36) = 5.13; P < 0.05). Pairwise comparisons reported that acute systemic injection
of 4 (10 mg/kg) improved STL time when compared to the (Saline)-treated group
[F(1,12) = 9.90; P < 0.05]. This 4-induced improvement of latency time was not
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reversed following ZOL (10 mg/kg) injection [F(1,12) = 0.04; p=0.84: Saline + 4 vs. 4
+ ZOL]. Also, systemic injection of PYR (10 mg/kg) failed to reverse the 4-induced
improvement of latency time when compared to the 4 (10 mg/kg)-treated group
with [F(1,12) = 1.08; P=0.32]. Also, neither Saline + Saline vs. PYR + Saline, nor
Saline + Saline vs. ZOL + Saline differences were significant (p=0.77 and p=0.76,
respectively).
4.10 Effects of H3R antagonist 4 on consolidation
Figure 22 shows the effects of H3R antagonist 4 (2.5, 5, and 10 mg/kg, i.p.),
PIT (10 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on memory consolidation in the onetrial inhibitory avoidance task. One-way analysis of variance showed that treatment

Figure 22: Effect of post-training administration of H3R antagonist 4 on
consolidation in an inhibitory avoidance conditioned response in male adult rats.
Gray columns represent the mean step-through latencies measured during the
retention test (test latencies) and black columns the mean step-through latencies
measured during the training trial before the delivery of the foot-shock (pre-shock
latencies). Rats were injected with 4 (2.5, 5 or 10 mg/kg, i.p.), PIT (10 mg/kg, i.p.),
or donepezil (DOZ, 1 mg/kg, i.p.) immediately after the training trial. Memory
retention was measured 24 h after training. Data are expressed as mean ± SEM
(n=7).
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with PIT (10 mg/kg, i.p.), DOZ (1 mg/kg, i.p.), and H3R antagonist 4 (2.5, 5, and 10
mg/kg, i.p.) injected immediately after the training session, did not enhance the
effects on step-through latencies [F(5,41) = 0.50; P=0.78] measured 24 h later. Among
the compounds tested, rats pretreated with 4 (2.5, 5, and 10 mg/kg, i.p.), PIT (10
mg/kg, i.p.), and DOZ (1 mg/kg, i. p.) showed no significant effect on mean stepthrough latencies when compared with the saline-treated group with [F(1,13) = 2.51,
F(1,13) = 0.43, and F(1,13) = 0.57, F(1,14) = 2.54, and F(1,12) = 2.57; all NS], respectively.
4.11 Effects of H3R antagonist 4 on retrieval
Figure 23 displays the effects of H3R ligand 4 (2.5, 5, and 10 mg/kg, i.p.),
PIT (10 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on the retrieval process. One-way
analysis of variance showed that treatment 4 (5 and 10 mg/kg, i.p.) and DOZ (1
mg/kg, i.p.) injected before the retention test exerted a significant effect on stepthrough latencies with [F(1,12) = 5.11, F(1,12) = 9.08, and F(1,15) = 2.59; all P < 0.05],
respectively. However, the step-through latencies of rats injected with 4 (2.5 mg/kg,
i.p.), and 10 mg/kg PIT were not significantly different from saline-treated with
[F(1,12) = 3.46; p=0.09] and [F(1,14) = 0.19; p=0.67], respectively, all NS.
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Figure 23: Effect of pre-retrieval administration of H3R antagonist 4 on retrieval in an
inhibitory avoidance conditioned response in male adult rats. Gray columns represent
the mean step-through latencies measured during the retention test (test latencies) and
black columns the mean step-through latencies measured during the training trial
before the delivery of the foot-shock (pre-shock latencies). Rats were injected with 4
(2.5, 5 or 10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), or donepezil (DOZ, 1 mg/kg, i.p.) 30
min before the retention test. *P < 0.05 for mean step-through latencies vs. the value of
the saline group. Data are expressed as mean ± SEM (n=7).

4.12 Effect of PYR and ZOL on the H3R antagonist 4-provided memory
improvement of retrieval in an inhibitory avoidance conditioned response
Figure 24 shows the results of the experiment in which it was tested whether
the H3R antagonist 4 (10 mg/kg)-induced improvement of retrieval was mediated
through histaminergic neurotransmission. For this purpose, a group of rats (n=7 for
each group) was injected with Saline + 4 (10 mg/kg), with Saline + 4 (10 mg/kg) +
PYR (10 mg/kg), or with 4 ( 10 mg/kg) + ZOL (10 mg/kg) 30 min before the test
session.
As depicted in Figure 24, one-way ANOVA repeated measure with treatment
as the between-subject factor indicated a significant effect of this factor indicated a
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significant effect of this factor on latency time [F(5,36) = 4.42; P < 0.05). Pairwise
comparisons reported that acute systemic injection of 4 (10 mg/kg) improved STL
time when compared to the (Saline)-treated group [F(1,12) = 7.86; P < 0.05]. This 4-

Figure 24: Effect of PYR and ZOL on retrieval improvement of H3R antagonist 4 in
an inhibitory avoidance conditioned response in rats. Gray columns represent the
mean STLs measured during the retention test (test latencies) and black columns the
mean STLs measured during the training trial before the delivery of the foot-shock
(pre-shock latencies). Rats were injected with Saline + 4 (10 mg/kg), 4 (10 mg/kg) +
PYR (10 mg/kg), 4 (10 mg/kg) + ZOL (10 mg/kg), Saline + PYR (10 mg/kg), or
Saline + ZOL (10 mg/kg) 30 min before the test session. *P < 0.05 for mean STLs
vs. the value of the (Saline)-treated group. #P < 0.05 for mean STLs of 4 (10 mg/kg)
+ ZOL (10 mg/kg)-treated group vs. the value of the Saline + 4 (10 mg/kg)-treated
group. Data are expressed as mean ± SEM (n=7).

induced improvement of latency time was reversed following ZOL (10 mg/kg)
injection [F(1,12) = 0.02; p=0.88: Saline + Saline vs. 4 + ZOL]. However, systemic
injection of PYR (10 mg/kg) failed to reverse the 4-induced improvement of latency
time when compared to the 4 (10 mg/kg)-treated group with [F(1,12) = 0.19; p=0.67].
Also, neither Saline + Saline vs. PYR + Saline, nor Saline + Saline vs. ZOL + Saline
differences were significant (p=0.85 and p=0.80, respectively).
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4.13 Effects of H3R antagonist 4 on locomotor activity and anxiety levels
We used the OFT to rule out possible intrinsic impairment of spontaneous
locomotor activity or anxiety measures. Locomotor activity and anxiety levels were
measured by the number of line crossings in the arena and time spent in the center or
periphery in the arena. One-way analysis of variance showed that, compared with
vehicle, H3R antagonist 4 (2.5, 5, and 10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), and DOZ
(1 mg/kg, i.p.) had no effect on number of line crossings, [F(5,36) = 0.60, p=0.70]
(Figure 25A). Similarly, no significant treatment differences were found with regard

Figure 25: Number of line crossing (A) and time spent in center and periphery (B) in
total area of an open field following acute systemic administration of H3R antagonist
4. In the open field test, H3R antagonist 4 (2.5, 5 or 10 mg/kg, i.p.) had no effect on
number of line crossing (A) and time spent in center or periphery (B). Data are
expressed as mean ± SEM (n=7).

to time spent in the central area or periphery (i.e. level of anxiety) with [F(5,36) = 0.85,
p=0.52] and [F(5,36) = 0.02, p=0.99], respectively (Figure 25B).
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Chapter 5: Discussion

Examined compounds 1-12 differed in their chemical structures in the linker
or spacer lengths (Figure 7) being three, five, or six methylene groups as well as in
the lipophilic substitution being various groups of known AEDs (Table 3). All
compounds chosen for the current study have, as previously confirmed, high in vitro
hH3R affinities with observed pKi values in the range 6.22 to 8.08 (Table 3).
Table 3: Chemical structures and in vitro antagonist affinities of test compounds 1-12 for
human histamine H3Rs stably expressed in CHO-K1 cells.
MWta
[g/mol]

hH3R
pKib

1

499.50*

7.37

2

467.25

6.25

3

348.41

6.46

4

379.51

8.08

5

379.49

7.32

6

393.52

7.42

7

393.52

6.81

Compound

Structure

54
MWta
[g/mol]

hH3R
pKib

8

427.53

7.06

9

393.52

7.13

10

407.54

7.07

11

421.53

7.41

12

441.56

6.83

Pitolisant

385.21

7.57

Compound

Structure

a

Molecular weight calculated as hydrogen oxalate. b[125I]Iodoproxyfan binding assay at human
H3R stably expressed in CHO-K1 cells, n = 3. *Molecular weight calculated as dioxalate.

In the current study, all experiments were conducted with PHT (10 mg/kg,
i.p), VPA (100 mg/kg, i.p.), or (300 mg/kg, i.p.) in MES-, PTZ- and STR-induced
seizure models, respectively. These were the minimal doses of PHT and VPA that
protected animals against MES-, PTZ-, and STR-induced seizures without mortality.
The test compounds (1-12) varied in their level of protection in the three seizure
models used in the current study. In MES-induced experiments, H3R antagonists 4,
8, 10, 11, and 12 showed the best protection against MES-induced (Figure 13)
convulsion in rats pretreated with 10 mg/kg, i.p. when compared with the salinetreated group. Accordingly, the anticonvulsant effects obtained were expressed in the
order of increasing in vivo potency (1 ~ 2 ~ 3 ~ 5 ~ 6 ~ 7 ~ 9 - group I) < (7 ~ 10 ~
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11 ~ PIT – group II) < (4 - group III), whereas values for in-vitro H3R affinity
measured with pKi values were 2 < 3 < 7 < 12 < 8 < 10 < 9 < 5 < 1 < 11 < 6 < PIT <
4. It was found that the introduction of a three methylene-spacer together with the
tert-pentyl moiety significantly increased the lipophilic properties as observed for
H3R antagonist 4 (c.f. compound 4 vs. 1-3 and 5-12). Such an effect was, also,
beneficial for the protective in-vivo anticonvulsant effect of H3R antagonist 4 was
comparable to that observed for the standard H3R antagonist PIT. Interestingly, PIT
and H3R antagonist 4 incorporate the same structural pharmacophores, namely a
piperidinylpropyloxy moiety, known to be responsible for H3R antagonist affinity
(Figure 26).

Figure 26: Structural similarities (red) and differences (blue) between H3R antagonist
4 and the standard H3R antagonist PIT.

In contrast, introduction of longer alkyl spacers (5 or 6 methylene groups),
e.g. H3R antagonists 5-12, failed to further increase in vitro antagonist affinity for
hH3Rs as well as to provide higher in vivo protective effects in MES-induced seizure
model. Nonetheless, it may be concluded that H3R ligands with the
piperidinylpropyloxy moiety (e. g. PIT and H3R antagonist 4) as a common
structural feature showed the best protection among the compounds 1–12.
The results observed in the MES model indicated that H3R antagonist 4
offered the best protection against MES-induced convulsions when rats were
pretreated with 10 and 15 mg/kg i.p., as compared with standard H3R antagonist PIT
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(10 mg/kg, i.p.), the saline-treated group, and the H3R antagonist 4-treated group at a
dose of 5 mg/kg, i.p (Figure 14). Accordingly, the observed results indicated a doseresponse relationship of the protection observed and the presence of a ceiling for
H3R antagonist 4 in MES-induced seizures. Notably, the protective effect observed
for H3R antagonist 4 (10 or 15 mg/kg, i.p.) was comparable to that observed in the
group pretreated with the reference drug PHT (10 mg/kg, i.p.). Interestingly, these
results are in agreement with recent studies that described the dose-dependent
anticonvulsant effect of H3R antagonists in MES-induced seizures in animal models
and PIT in a photosensitivity seizure model in adult patients (Kasteleijn-Nolst
Trenite et al., 2013; Sadek et al., 2014a, 2014b, 2013). Further experiments showed
that the protective effect of H3R antagonist 4 was reversed when rats were pretreated
with 10 mg/kg i.p., of the CNS penetrant histamine H1R antagonist PYR 30 min, or
with the selective H3R agonist R-()-methyl-histamine (RAMH) (10 mg/kg, i.p.) 15
min before MES challenge (Figure 15). Importantly, PYR (10 mg/kg) and RAMH
(10 mg/kg) administered alone did not show either a protective or an epileptogenic
effect in rats challenged by the MES-induced seizure. These findings suggest that the
protective action of H3R antagonist 4 in the MES-induced seizure is mediated, at
least partially, through blockade of H3Rs and interactions of released histamine with
postsynaptically located histamine H1Rs, and these findings are in agreement with
the previously observed protective effects for H3R antagonists (Kakinoki et al.,
1998; Sadek et al., 2014a). H3Rs are auto-receptors located on presynaptic
histaminergic terminals with an inhibitory action on the synthesis and release of
histamine (Arrang et al., 1983). Blockade of these receptors by selective H3R
antagonists, such as compound 4, would lead to an enhanced neuronal histamine
release in the brain, resulting in an anticonvulsant effect. Similar effects of
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imidazole-based as well as non-imidazole-based H3R ligands have been reported
previously to be reversed either by H3R agonists or by H1R antagonists, but not by
H2R antagonists, signifying an interaction of the H3R antagonism-released histamine
with H1Rs on postsynaptic neurons (Bhowmik et al., 2012; Kakinoki et al., 1998;
Sadek et al., 2014a, 2014b, 2013).
H3R antagonist 4, on the other hand, failed to offer significant protection
against chemically (PTZ or STR)-induced seizures (Figure 16 and 19) Notably, PIT
(10 mg/kg i.p.) had no significant effect in chemically-induced seizures. This could
be due to differences in the mechanism or type of seizures in each model.
Accordingly, MES is a model of generalized tonic-clonic seizures (Loscher et al.,
1991a), while PTZ (60 mg/kg, i.p.) induces generalized myoclonic and/or tonicclonic seizures (Loscher et al., 1991b). Moreover, electrically-induced seizures result
from stimulation of all neuronal pathways and the insult only lasts for a short time
(one second). However, in chemically-induced seizures, the trigger remains until the
elimination of the proconvulsant, e.g. PTZ or STR. Furthermore, chemical agents
affect only some neuronal pathways, e.g. PTZ provides blockage of tbutylbicyclophosphorothionate (TBPS) site at GABAA receptors (Olsen, 1981) and
reduces GABA neurotransmission (Corda et al., 1991). It is noteworthy that most
marketed antiepileptic drugs were not effective in all seizure models. For instance,
carbamazepine, oxcarbazepine and PHT are highly effective in the MES-induced
model, however, they lack any protective effects against seizures induced by PTZ,
STR or picrotoxin (Swinyard et al., 1986, White, 1999). In contrast, ethosuximide
and tiagabine, which provide high protection in chemically-induced seizure models,
are inactive in the MES-induced model when used at nontoxic doses (White, 1999).
These characteristic preclinical activities explain the effectiveness of PHT,
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carbamazepine and oxcarbazepine but not ethosuximide or tiagabine in patients with
generalized tonic-clonic seizures. Similarly, H3R antagonist 6 that has no
pronounced effect in MES test or STR-induced seizures dose dependently suppressed
PTZ-induced seizures (Figure 17). Notably, H3R antagonist 6 completely abolished
seizures after acute systemic pretreatment with 10 and 15 mg/kg, and the protection
observed was similar to that provided by the standard AED VPA 100 mg/kg.
Interestingly, the protection observed for H3R antagonist 6 in PTZ-induced seizure
model was partially reversed (Figure 18) upon acute systemic co-administration of
PYR indicating that part of this effect was H1R-dependent. Other neurotransmitters
like GABA may be involved in the protective mechanism. It can, also, be
hypothesized that H3R antagonists could also block histamine H3 heteroreceptors
that control the release of other neurotransmitters including GABA (Brown et al.,
2001, Haas et al., 2008). In a previous study the H3R antagonist clobenpropit was
found to increase GABA release and to protect against NMDA-induced
excitotoxicity in rat cultured cortical neurons (Dai et al., 2007a).
In a further experiment, H3R antagonists 8 and 11 offered some protection in
the STR-induced seizure model (Figure 19), however, not as effective as standard
AED VPA (300 mg/kg, i.p). It is well known that STR is a competitive antagonist of
the inhibitory amino acid glycine. Consequently, the inability of H3R antagonist 4 to
protect against STR-induced seizure suggests little or no effect on the glycine
receptors, since the mechanism underlying STR-induced convulsions is thought to be
attributed to its blocking effect on glycine receptors in brain as well as in spinal cord
(Sowemimo et al., 2011).
Several AEDs negatively influence memory (Hermann et al., 2010).
Therefore, it is essential to probe such troublesome side effects in novel antiepileptic
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treatment. Histamine, agents that increase brain histamine (e.g. L-histidine), and H3R
antagonists have been found to improve different measures of cognition in a plethora
of preclinical behavioral studies (Table 1) (reviewed by Esbenshade et al., 2008,
Zlomuzica et al., 2015). Increment of wakefulness and cortical fast rhythms are
aspects of cognition that have been approved with PIT in the clinics (Dauvilliers et
al., 2013, Kasteleijn-Nolst Trenite et al., 2013). Several H3R antagonists including
PIT are currently under clinical investigation for their efficacy in the treatment of
cognitive disorders (Brioni et al., 2011, Zlomuzica et al., 2015). Since the
antiepileptic effect observed for H3R antagonist 4 in the MES model depends on its
histamine neurotransmission modulating effect, the question remained whether such
central histamine modulation has any impact on memory processes in the same
animal species.

Figure 27: Chemical structure, in vitro affinities, and in vivo potency of H3R antagonist
4. aCentral histamine H3R assay in vivo after p.o. administration to mice, n=3 (Garbarg et
al., 1989, Garbarg et al., 1992, Ligneau et al., 1998, Lazewska et al., 2006).
b 125
[ I]Iodoproxyfan binding assay at human H3R stably expressed in CHO-K1 cells, n=3
(Ligneau et al., 1994, Ligneau et al., 2000, Lazewska et al., 2006). c[3H]Histamine
binding assay performed with cell membrane preparation of Sf9 cells transiently
expressing the human histamine H4R and co-expressed with Gαi2 and β1γ2 subunits
n=3(Meier et al., 2001, Amon et al., 2007, Isensee et al., 2009, Tomasch et al., 2013).
d 3
[ H]Pyrilamine binding assay performed with cell membrane preparation of CHO-hH1R
cells stably expressing the human H1R; n=3(Schibli and Schubiger, 2002, van Staveren
and Metzler-Nolte, 2004). eThe affinity for (2)-adrenoceptors was evaluated by
radioligand binding assays to rats cortex membrane using [ 3H]clonidine (Barbaro et al.,
2002, Betti et al., 2002, Handzlik et al., 2008).
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Therefore, the non-imidazole-based H3R antagonist 4 with high H3R in vitro
affinity, excellent in vitro selectivity profile, and in vivo antagonist potency (Figure
27) has in the current project been investigated for its behavioral effects on
acquisition, consolidation and retrieval processes in a one-trial inhibitory avoidance
paradigm in rats. Given that motor activity could mask the effects of H3R antagonist
4 on learning and memory, we also used an open field test (OFT) to evaluate activity
and anxiety in the same animals. Memory is often considered to be a process that has
several stages including acquisition, consolidation, and retrieval (Abel and Lattal,
2001). Usually, tasks that have been designed to modulate memory processes consist
of a training session followed, after 24 or more hours, by a test session. In the present
study, acute systemic administration with 2.5 mg/kg of H3R antagonist 4 enhanced
memory acquisition when compared with the saline-treated group. However, higher
doses (5 and 10 mg/kg, i.p.) of H3R antagonist 4 did not affect acquisition, indicating
that the effect is dose-dependent (Figure 20). The observed dose-dependent
facilitating effect of H3R antagonist 4 on acquisition is in agreement with a previous
study in which the reference H3R antagonist GT-2331 showed dose-dependent
memory-enhancing effects on repeated acquisition in an inhibitory avoidance
paradigm (Fox et al., 2002). In their study, rats treated with GT-2331 (1 mg/kg, i.p.)
performed significantly better than those injected with a higher dose (30 mg/kg, i.p.).
Nonetheless, further behavioral tests should be conducted to investigate whether the
improving effect of H3R antagonist 4 (2.5 mg/kg) on acquisition is mediated through
neurotransmission other than histamine, since PYR and ZOL failed to reverse the
effects of H3R antagonist 4 (Figure 21). In contrast, our results showed that acute
systemic administration of H3R antagonist 4 in the post-training session failed to
facilitate consolidation (Figure 22). These results are in disagreement with previous
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findings highlighting the critical role of H3Rs in consolidation as a stage of memory
processing (de Almeida and Izquierdo, 1986). Nonetheless, in the latter study
different animal species and step-down inhibitory avoidance procedures were used
which could explain the discrepancy between the studies (Bernaerts et al., 2004,
Charlier et al., 2013). Our results also showed that systemic pre-testing
administration of H3R antagonist 4 (5 and 10 mg/kg, i.p.) improved memory (Figure
23), which indicates that this compound when administered at higher doses facilitates
dose-dependently the retrieval stage. These results for H3R antagonist 4 are in
agreement with previous studies in which systemic administration of various
imidazole-based H3R antagonists were found to enhance memory retrieval in a dosedependent manner in an object recognition task in rats (Orsetti et al., 2002, Pascoli et
al., 2009, Bardgett et al., 2010). Interestingly, the procognitive activity of H3R
antagonist 4 (10 mg/kg, i.p.) on retrieval was in a another experiment completely
reversed when rats were pretreated with the centrally acting H2R antagonist
zolantidine (ZOL, 10 mg/kg, i.p.) but not the centrally acting H1R antagonist (PYR,
10 mg/kg, i.p.), indicating that histaminergic pathways through activation of H2Rs
appear to be participating in neuronal circuits involved in the retrieval processes
(Figure 24).
Importantly, the results observed in the current study for H3R antagonist 4 at
doses of 2.5, 5, and 10 mg/kg, i.p., did not affect spontaneous locomotor activity and
anxiety levels of male Wistar rats (Figure 25). This finding is important, since
improved performance in an inhibitory avoidance task can be the result of numerous
variables unrelated to memory acquisition such as alterations in spontaneous
locomotor activity or emotional response (McGaugh and Roozendaal, 2009, Charlier
et al., 2013). Therefore, it is unlikely that H3R antagonist 4 administered before the
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conditioning session increased retention through a nonspecific effect during the
training session.
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Chapter 6: Conclusion

In conclusion (Figure 28), acute systemic administration of novel and highly
affine H3R antagonists (1-12) provided different protective effects against in a
variety of rat seizure models. Through histaminergic-neurotransmission, H3R
antagonist 4 dose-dependently displayed the greatest anticonvulsant activity in MESinduced seizures. However, H3R antagonists 6, 8, and 11 provided the highest
protection in PTZ-, and STR-induced seizure models, respectively. Moreover, acute
systemic administration of H3R antagonist 4 dose-dependently improved different
aspects of memory, especially at the level of retrieval. These results enhance further

Figure 28: Schematic simplified illustration of the study including the most essential
points regarding theory, objectives, experiments and concluding remarks.
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the potential utility of histamine H3R antagonists in the treatment of epilepsy and
other neuropsychiatric disorders typified by cognitive deficits.
6.1 Limitations of the study
- No further experiment were conducted to explain other mechanisms by which
H3R antagonist 6 protect against PTZ-induced seizures other than the partial
contribution of H1 receptors. However, possible mechanisms can be deduced
from the available literature with other H3R antagonists or histamine.
- No additional mechanistic experiments were done to understand the pathway
by which H3R antagonist 4 improve acquisition at 2.5 mg/kg.
- Based on the main objectives of the study, only one compound of the tested
H3R antagonists was selected depending on its seizure control and histaminedriven mechanism of action. The memory effect of other less effective antiseizure H3R antagonist can be extrapolated or assumed from H3R antagonist 4
effects.
- Due to current unavailability of other optimized memory rat models in our
laboratory, cognitive effects of H3R antagonist 4 was analyzed based on
passive avoidance test only.
6.2 Future direction
- Explore the behavioral activity of H3R antagonist 4 in other memory models
for example spatial memory utilizing the Y-maze or the Place recognition test.
- Test H3R antagonist 4 or other effective compounds like 6, 8 and 11 in other
seizure models especially those that represent resistant forms of epilepsy to
expand the possible therapeutic utility of these compounds and other H3R
antagonists.
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- Explore the effects of the most effective anticonvulsant H3R antagonists 1-12
against low-magnesium- or chemically-induced epileptiform discharges at
CA1/CA3 regions of hippocampus at the level of brain slices with easier and
reliable access of compounds. Through this method possible mechanisms of
beneficial effects can be thoroughly investigated.
- Further analyze the mechanisms of anticonvulsant activity of H3R
antagonists through patch-clamp or whole-cell recording in individual isolated
CA1/CA3 neurons.
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